Cargando…
Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer
The overall five-year survival rate of pancreatic cancer has hardly changed in the past few decades (less than 10%) because of resistance to all known therapies, including chemotherapeutic drugs. In the past few decades, gemcitabine has been at the forefront of treatment for pancreatic ductal adenoc...
Autores principales: | Yang, Jianhui, Xu, Jin, Zhang, Bo, Tan, Zhen, Meng, Qingcai, Hua, Jie, Liu, Jiang, Wang, Wei, Shi, Si, Yu, Xianjun, Liang, Chen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539929/ https://www.ncbi.nlm.nih.gov/pubmed/34681603 http://dx.doi.org/10.3390/ijms222010944 |
Ejemplares similares
-
The role of ferroptosis regulators in the prognosis, immune activity and gemcitabine resistance of pancreatic cancer
por: Tang, Rong, et al.
Publicado: (2020) -
Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going
por: Liang, Chen, et al.
Publicado: (2017) -
Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis
por: Zhang, Yiyin, et al.
Publicado: (2019) -
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity
por: Tang, Rong, et al.
Publicado: (2020) -
Circular RNA in pancreatic cancer: a novel avenue for the roles of diagnosis and treatment
por: Rong, Zeyin, et al.
Publicado: (2021)